Shivering is distressing for the patients and may exacerbate postoperative pain, increase intracranial pressure, and induce cardiopulmonary complications 3 . Many drugs have been used to treat shivering, including pethidine, doxapram, tramadol, ketanserin, clonidine, propofol, physostigmine, and nalbuphane 4 . Among these drugs, pethidine is often recommended. Although its mechanism of action is not fully elucidated, much evidence suggests the drug's special anti-shivering activity is mediated by its -opioid receptor activity 5 . Nalbuphine, a mixed agonist-antagonist opioid, has a high affinity foropioid receptors. Theoretically, nalbuphine may have significant anti-shivering effects on perioerative shivering in regional anaesthesia. Shivering can be very unpleasant and physiologically stressful for the patient after enjoying the comforts of modern anaesthetics. Mild shivering increases oxygen consumptions to a level that is produced by light exercise, whereas severe shivering increases metabolic rate and oxygen consumption up to 100-600%. It may induce arterial hypoxaemia, lactic acidosis, increases IOP and ICP and interferes with ECG monitoring, pulse rate, BY etc. 3, 4, 5 Shivering may be detrimental to the patients with low cardio respiratory reserves 6 . It is uncomfortable to the parturient as well as to the operating room personnel, especially during regional anaesthesia. Various methods are available for the control of shivering during anaesthesia. Non-pharmacological methods using equipments to maintain normothermia are effective but may be expensive and are not practical in all the settings. Pharmacological methods using various drugs like Pethidine, Clonidine, Doxapram, Ketanserine, Tramadol, Nefopam etc. have been tried which are simple, cost effective and easily available. Here we have compared Nalbuphine, a newer synthetic opioid with Pethidine, the gold standard drug for the treatment of shivering, in the quest for more safer and efficacious drug. We conducted this study to compare the efficacy, potency, haemodynamics effects and complications or side effects of Nalbuphine with that of Pethidine for the control of shivering. 
METHOD AND MATERIAL:

Shivering grades
Grade 0 No Shivering.
Grade I
Mild fasciculations of face or neck, ECG disturbances in absence of voluntary activity of arms.
Grade 2 Visible tremors involving more than one group of muscle.
Grade 3 Gross muscular activity involving the entire body, bed shaking
All the patients who experienced shivering were randomly divided into Group N and Group P. Group N received 5mg Nalbuphine and Group P received 25mg Pethidine after initiation of shivering. All the patients were assessed for shivering grades, its disappearance, haemodynamics status, and complications if any. Patients were observed at intervals of 1 min till 5 mins, and thereafter at 10, 20, 30, 45, and 60mins.Pulse rate, BY, SP02, Respiratory rate, and temperature were noted immediately after regional anaesthesia, and also during shivering, and thereafter the drug administration at regular intervals. Recurrence of shivering was also noted and an additional dose of either Nalbuphine 5mg or Pethidine in a dose of 25mg LV was given in respective groups. Statistical analysis was done by EPI infoversion 6.04 January 2001 software package using unpaired student 't' test and chi square test.
RESULTS
In our study, both the groups were comparable with regards to age, weight, and ASA physical status (PS).
There was no significant difference found in duration of surgery, as well as shivering grades at the start of study between the two groups ( Table-III) . NS*= Statistically Significant.
The onset of disappearance of shivering was found at around 1 minute and 3 minutes in Group N and Group P respectively. Regarding the disappearance of shivering in both groups, we found a statistically significance difference as shown in the Haemodynamically there was no significant difference found in two groups as shown the Table-4 . Around 40-60% of the patients under regional anaesthesia develop shivering, though it is found commonly after general anaesthesia. 8 The probable mechanism under regional anaesthesia could either be a result of decrease in core body temperature or misinformation from receptors. 9 The factors causing decrease in core body temperature include, sympathetic block causing peripheral vasodilatation, increased cutaneous blood flow resulting in increased heat loss through skin, cold operating room, rapid IV infusion for preload. Earlier studies have showed better results with Nalbuphine group. 6 The findings were in condolence with other studies which noted 8% with Nalbuphine group and 13-50% in Pethidine group' 1 ' 13 Thus various studies including ours there was higher rate of recurrence with Pethidine in comparison to Nalbuphine . The second dose of the drug controlled the shivering completely but the possibility of respiratory depression with Pethidine should be borne in mind. The probable reason for recurrence of shivering could be result of low plasma concentration of the active drug, when hypothermia is still persisting and individual variations in the core temperatures. Nalbuphine produced a rapid and potent anti-shivering effect similar to that observed with pethidine. After each treatment, there were no significant differences among groups in blood pressure, heart rate, respiratory rate, and arterial oxygen saturation. Because these variables were similar, only data obtained 0, 5, and 30 min after the treatments are shown ( Table-III) .
Till date it is not clear whether higher shivering grades requires a higher doses of the drug. In our study both the drugs gave good and better haemodynamic stability throughout the course of the study in all the patients. Nalbuphine is effective in treating shivering under regional anaesthesia due to its rapid onset, effective control, less recurrence rate and minimum side effects in a dose of 5mg. when compared to Pethidine 25mg. Similarly Nalbuphine was effective and safe in comparison to Pethidine for control of shivering as noted earlier 3 even recommend for Nalbuphine on prophylactic basis also.
CONCLUSION:
IV administration of nalbuphine, a σ-receptor agonist, provides a rapid and potent anti-shivering effect and the effect of nalbuphine is similar to that of pethidine in an equianalgesic dose. Nalbuphine may be an alternative to pethedine for treating perioperative shivering.
